Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study
Silverberg, J.I., Pinter, A., Alavi, A., Lynde, C., Bouaziz, J.‐D., Wollenberg, A., Murrell, D.F., Alpizar, S., Laquer, V., Chaouche, K., Ahmad, F., Armstrong, J.M., Piketty, C.
Published in Journal of the European Academy of Dermatology and Venereology (01.07.2021)
Published in Journal of the European Academy of Dermatology and Venereology (01.07.2021)
Get full text
Journal Article
134 Clinical response to IL-22RA1 blockade is associated with reduction of systemic inflammation
Thaçi, D., Gooderham, M., Laquer, V., Lynde, C., Reich, A., Soong, W., Litman, T., Madsen, D., Martel, B., Soerensen, O.E., Worm, M.
Published in Journal of investigative dermatology (01.11.2023)
Published in Journal of investigative dermatology (01.11.2023)
Get full text
Journal Article
LB1702 Lebrikizumab does not impact vaccine-induced immune responses: Results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis
Soung, J., Laquer, V., Merola, J.F., Forman, S., Elmaraghy, H., Meskimen, E., Hu, C., Natalie, C., Pierce, E., Torisu-Itakura, H., Gil, E., Jarell, A.
Published in Journal of investigative dermatology (01.09.2023)
Published in Journal of investigative dermatology (01.09.2023)
Get full text
Journal Article
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Kwatra, Shawn G., Yosipovitch, Gil, Legat, Franz J., Reich, Adam, Paul, Carle, Simon, Dagmar, Naldi, Luigi, Lynde, Charles, De Bruin-Weller, Marjolein S., Nahm, Walter K., Sauder, Maxwell, Gharib, Rola, Barbarot, Sebastien, Szepietowski, Jacek C., Conrad, Curdin, Fleischer, Alan, Laquer, Vivian T., Misery, Laurent, Serra-Baldrich, Esther, Lapeere, Hilde, Ahmad, Faiz, Jabbar Lopez, Zarif K., Piketty, Christophe, Ständer, Sonja
Published in The New England journal of medicine (26.10.2023)
Published in The New England journal of medicine (26.10.2023)
Get full text
Journal Article
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
Blauvelt, Andrew, Ladizinski, Barry, Prajapati, Vimal H., Laquer, Vivian, Fischer, Alison, Eisman, Samantha, Hu, Xiaofei, Wu, Tianshuang, Calimlim, Brian M., Kaplan, Blair, Liu, Yingyi, Teixeira, Henrique D., Liu, John, Eyerich, Kilian
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial
Blauvelt, A, Ladizinski, B, Prajapati, VH, Laquer, V, Fischer, A, Eisman, S, Wu, T, Vigna, N, Teixeira, HD, Liu, J, Eyerich, K
Published in BRITISH JOURNAL OF DERMATOLOGY (2022)
Get full text
Published in BRITISH JOURNAL OF DERMATOLOGY (2022)
Conference Proceeding
A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA and narrowband red light in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT)
Laquer, V, Bruce, S, Schlesinger, T, Zeitouni, N, Torres, A, Cohen, J, Tu, J, Hanke, W, Goldman, M, Ozog, D, Markowitz, O, Gold, M, Nestor, M, Berman, B, Munavalli, G, Pariser, D
Published in Skin (Milwood, N.Y.) (09.11.2019)
Published in Skin (Milwood, N.Y.) (09.11.2019)
Get full text
Journal Article